Leerink Partners Maintains a Buy on Lantheus Holdings (LNTH) With a $99 PT

Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the best high growth low PE stocks to invest in now. In a report released on August 21, Faisal Khurshid from Leerink Partners maintained a Buy rating on Lantheus Holdings, Inc. (NASDAQ:LNTH) and set a price target of $99.00.

Lantheus Holdings, Inc. (NASDAQ:LNTH) reported its fiscal Q2 2025 results on August 6, with worldwide revenue for the quarter reaching $378.0 million. GAAP fully diluted earnings per share were $1.12, and free cash flow reached $79.1 million for the quarter.

Lantheus Holdings, Inc. (NASDAQ:LNTH) also announced the FDA’s acceptance of NDA for a new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026.

Lantheus Holdings, Inc. (NASDAQ:LNTH) provides diagnostic imaging and nuclear medicine products, developing products that support healthcare professionals in patient management and outcomes and help clinicians detect cardiovascular disease. The company’s operations are divided into the U.S. and International geographical segments.

While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.